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BACKGROUND: This epidemiological observational study aimed at determining the prevalence of malnutrition in non-selected adults
with cancer, to identify risk factors of malnutrition and correlate the results with length of stay and 2-month mortality.
METHODS: This prospective multicentre 1-day study conducted in 17 French Comprehensive Cancer Centres included 1545 patients.
Body mass index (BMI), weight loss (WL) in the past 6 months and age were routinely recorded according to the French national
recommendations for hospitalised patients; malnutrition was rated as absent, moderate or severe according to the level of WL and
BMI. Age, sex, tumour site, type of hospitalisation and treatment, disease stage, World Health Organisation performance status (PS)
and antibiotic therapy were the potential malnutrition risk factors tested. Follow-up at 2 months allowed to determine the correlation
with length of stay and mortality.
RESULTS: Malnutrition was reported in 30.9% of patients, and was rated as severe in 12.2%. In multivariate analysis, only pre-existing
obesity (BMIX30), PS X2 and head-and-neck or upper digestive cancers were associated with increased risk of malnutrition.
Antibiotics use was significantly higher in malnourished patients (35.5 vs 22.8%; Po0.001). Severe malnutrition was independently
associated with mortality. The median length of stay was 19.3±19.4 days for malnourished patients vs 13.3±19.4 days for others
(Po0.0001).
CONCLUSION: In French Comprehensive Cancer Centres, one out of three cancer patients are malnourished and this was associated
with a longer length of stay. Pre-existing obesity could be identified as a new risk factor for malnutrition in our cancer patient
population perhaps because of a misidentification or a delay in nutrition support in this category of patients.
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In cancer patients, malnutrition and weight loss (WL) have been
identified as being associated with worse outcome, impaired
quality of life and performance status (PS). In the often-cited study
by Dewys et al (1980), WL before treatment is reported in 54% of
3047 patients enrolled in 12 chemotherapy protocols and is linked
to the World Health Organisation (WHO) PS and outcome. Many
reviews have highlighted this high prevalence of malnutrition in
cancer patients, its potential for adverse effects on outcome and its
economic consequences (Nitenberg and Raynard, 2000; Norman
et al, 2008). On the other hand, published data of malnutrition
prevalence in populations of cancer patients are often given as a
function of localisation (Dewys et al, 1980; Bozzetti, 2009), tumour
stage (Andreyev et al, 1998; Segura et al, 2005) or treatment
(Dewys et al, 1980). Other prevalence data are available from
recent surveys of hospitalised patients, but cancer patients
generally represent only a limited proportion of the study
population, usually one in four (Correia and Waitzberg, 2003;
Pirlich et al, 2006) or even less (Kruizenga et al, 2003). Very
few surveys have explored large non-selected populations of
cancer patients treated at specialised centres in Europe (Nourissat
et al, 2007).
The objective of this epidemiological observational multicentre
‘one-day’ study in non-selected hospitalised adults with cancer was
to determine the prevalence of malnutrition during hospitalisation
in cancer centres and to identify potential risk factors for
malnutrition (such as age, sex, tumour site, type of hospitalisation
and treatment, disease, PS and antibiotic therapy). Patient follow-
up at 2 months was used to determine the association between
malnutrition, length of hospital stay (LOS) and mortality.
MATERIALS AND METHODS
This prospective epidemiological observational multicentre study
was conducted in voluntary cancer centres in France. Between
October 2007 and January 2008, each cancer centre chose 1 day to
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sconduct the study, except Mondays and Fridays (usually associated
with a higher number of hospital admissions and discharges)
and weekends. All adult hospitalised patients from every unit or
ward were included on the same day. Patients admitted for 1-day
hospitalisation (outpatient clinic) were also eligible if possible.
The only exclusion criteria were age below 18 years, absence of
malignant diagnosis at the end of stay and patients in agony.
Owing to a lack of staff to evaluate all patients admitted at a given
centre, it was possible to conduct the study in only a limited
number of wards, but an exhaustive investigation of all patients
was performed. The study was observational and required no
particular intervention; therefore, it was not subjected to ethics
committee agreement (Claudot et al, 2008). The database was
registered with the French national authorities (CNIL, Commission
Nationale de l’Informatique et des Liberte ´s). Computerised data
were processed anonymously. Information was given to all patients
on the day of the study.
Malnutrition was defined following the recommendation of
the French health authority (Haute Autorite ´ de Sante ´) (www.has-
sante.fr/portail/upload/docs/application/pdf/denutrition_personne_
agee_2007_recommandations.pdf)(www.has-sante.fr/portail/upload/
docs/application/pdf/denutrition_rap_2006_09_25_14_20_46_269.
pdf) and by the Nutricode labelled by the French society of
parenteral and enteral nutrition 2006 (http://www.nutricode.fr/)
using age (in years), BMI (in kgm
 2) and WL (in percentage over
the previous 6 months). Malnutrition was rated as absent,
moderate or severe (Table 1). Patients’ weight (W) and height
(H) were recorded during the hospital stay, as usually recom-
mended in France for hospitalised patients. If not applicable,
inability to measure weight or height was reported. When it was
not possible to measure the patient’s height, knee height
measurement was performed and patient stature was calculated
using the following formulas (Chumlea et al, 1985):
  For women: H¼84.88 (0.24 age in years)þ(1.83 knee
height in centimetres) and
  for men: H¼64.19 (0.04 age in years)þ(2.02 knee height
in centimetres)
Patients were asked their weight 6 months before the study. When
they did not remember or were uncertain about it, information
was retrieved from patient records; when available, the values were
used for calculation of WL in percentage (%) using the following
ratio: ((W 6 months earlier current W)/100 W 6 months
earlier). Body mass index (BMI) was also calculated, such as
BMI¼W/H
2 in kgm
 2.
Other data collected on the day of the study were the following:
patient’s birth date and gender, type of hospitalisation (conven-
tional or outpatient), site of primary tumour, presence of distant
metastasis (yes or no), treatment received during the stay or in
relation to current hospitalisation (surgery, radiotherapy, chemo-
therapy), prescription of antibiotics during the stay until the day of
study (with the exception of antibiotic prophylaxis for surgery)
and type of nutritional support until the study day (dietetic
counselling, enteral or parenteral nutrition). Treatment was
defined as active when patients received active cancer treatment
with intention to cure or to obtain a remission (radiotherapy or
chemotherapy within 1 month, and surgery during the stay); many
patients
could be classified as receiving active treatment even if they had
metastatic disease. Hospitalisation for a complication of an active
treatment was also classified as active. Treatment was considered
palliative when patients received treatment (sometimes with anti-
neoplastic and/or only supportive therapies) to relieve symptoms
in the course of a progressive disease. Finally, disease was
considered terminal when patients were likely to die within
1 month. Patients were considered ‘under evaluation’ when the
decision for anti-neoplastic treatment was not actually made and
the patient was still undergoing diagnostic testing. Performance
status was determined on the day of the study using the definition
proposed by WHO. For patients recovering from recent surgery,
the value of PS at admission was possibly considered.
Two months after the study day, we determined the LOS
corresponding to the duration of stay from admission to discharge,
or to the day of the study plus 60 days if the patient was still in
hospital at that time. At this time, the patient status (alive, dead or
unknown) was also determined. Patients admitted for 1-day
hospitalisation were excluded from LOS analysis.
When BMI was not indicative of the presence of malnutrition
(418.5 or 421 before or after 70 years of age, respectively) and
WL could not be determined (absence of weight data 6 months
earlier), we considered that malnutrition could not be eliminated
and patients were not analysed for the association with risk factors
or outcomes.
For descriptive analyses, qualitative data were summarised as
frequencies, and results for continuous data were expressed
as means and s.d. Association between malnutrition and clinical
status was assessed using the w
2 test or Fisher’s exact test and
analyses of variance for categorical and continuous measurements,
respectively. A P-value of o0.05 was considered statistically
significant. Backward stepwise logistic regression analysis was
performed on variables associated with Po0.20. Results were
considered statistically significant when P-values were o0.05. The
same analysis was repeated to identify risk factors for mortality,
and a logistic regression was used to determine whether
malnutrition was an independent factor. Statistical analyses were
performed using STATA software (release 8.0, Stata Corporation,
College Station, TX, USA).
RESULTS
A total of 1545 patients, 885 women (57.2%) and 660 men (42.8%),
were included. The median age was 59.3±13.8 years, with 361
(23.4%) patients older than 70 years. The most frequent tumour
sites were the breast (24%), and the head and neck (12%); 825
(53%) patients had localised cancer, whereas 720 (47%) had meta-
static disease. Despite this metastatic status, most patients (80%)
experienced active treatment. Patient and treatment characteristics
are presented in Tables 2A and 2B.
The overall prevalence of malnutrition was 30.9%, with 18.6 and
12.2% cases of moderate or severe malnutrition, respectively. In
addition, 60.4% of patients reported a WL in the previous 6
months. Nutritional status could not be determined in 181 (12%)
patients, principally because there was no information regarding
their weight 6 months before the study. As mentioned in the
‘Materials and methods’ section, a normal BMI on the study day
was not considered sufficient to confirm the absence of malnutri-
tion because of the relatively low sensitivity of this indicator, which
identified only 12.4% of our 30.9% patients with malnutrition. The
nutritional status of patients is described in detail in Table 2A.
Briefly, 62% of malnourished patients received nutritional support
(vs 31.7% in the absence of malnutrition; Po0.001); this support
Table 1 Malnutrition, definition
Moderate malnutrition Severe malnutrition
Age p70 years Age p70 years
Weight loss over the past 6 months
X10% or BMI o18.5
Weight loss over the past 6 months
X15% or BMI o16
Age 470 years Age 470 years
Weight loss over the past 6 months
X10% or BMI o21
Weight loss over the past 6 months
X15% or BMI o18
Abbreviation: BMI¼body mass index.
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sincluded dietetic counselling alone (49.2%) or the use of oral
supplementation or artificial nutrition (12.8%).
The results of univariate analysis presented in Table 3 indicate
that male gender, presence of metastases, inpatient hospitalisation,
palliative care and radiotherapy are associated with the presence of
malnutrition. Obese patients (BMI X30, 6 months earlier) were
more prone to malnutrition (38.8 vs 28.5%; Po0.01); in these
patients, only the risk of severe malnutrition seemed significant
(OR¼2.26; 95% CI (1.5–3.4); Po0.0001). The prevalence of
malnutrition was moderately associated with the WHO PS, with a
major increase in patients with PSX 2. Finally, antibiotics intake
was significantly increased in malnourished patients (35.5 vs
22.8%; Po0.001).
In multivariate analysis (Table 4), only obesity at 6 months
before the study, poor functional status (PSX2) and head-and-
neck or upper digestive cancers were independently associated
with malnutrition.
Follow-up data at 2 months were available for 1081 patients.
Mortality (18.4%) was significantly higher in malnourished
patients than in the other group (26.7 vs 11.8%; Po0.0001; OR
2.7 (1.9–3.9)), especially in patients diagnosed with severe
malnutrition (37.1%; OR 4.4 (2.8–6.9)) compared with those with
mild symptoms (20.2%; OR 1.9 (1.2–2.9)). Mortality was also
higher in patients for whom no weight or height information was
available (25.7 vs 17.6%; P¼0.045). A multivariate analysis taking
into account major confounding factors such as age, gender, type
of stay, type of cancer, treatment, presence or absence of meta-
stases, antibiotics intake and PS showed that only severe malnutri-
tion was independently associated with mortality (Table 5).
The LOS was available for 879 inpatients. Malnutrition, either
moderate or severe, was significantly associated with prolonged
LOS. The median LOS was 19.3±19.4 days for malnourished
patients vs 13.3±19.4 days for others (Po0.0001). Patients for
whom no information on malnutrition status was available had an
LOS of 19.5±20.8 days, which was similar to results obtained in
malnourished patients. Patient nutritional status did not remain
significant when compared with other confounding factors
possibly associated with prolonged LOS. Only PS, head-and-neck
cancers, haematological malignancies and terminal stage remained
significantly associated with prolonged LOS (results not shown).
Table 2A Patient characteristics and type of disease
Patient
characteristics Total
Breast
cancer
Head and
neck
cancer
Colorectal
cancer
Haemato-
logical
malignancy
a
Gynaeco-
logical
cancer
b
Upper
digestive
cancer
c
Lung
cancer Others
d
(Number) % (1545) 100% (375) 24.3% (179) 11.6% (156) 10.1% (156) 10.1% (137) 8.9% (103) 6.7% (90) 5.8% (349) 22.6%
Age (years) 59.3±13.8 58.2±12.7 59.4±9.8 64.6±12.5 57.3±16.8 59±12.7 62.6±11 60.2±11.2 58±16.6
470 years 23% 19.7% 13.4% 34% 24.3% 19.7) 26.2% 18.9% 13.4%
M/F ratio 0.746 0.011 3.48 0.95 1.48 0 2.43 1.43 0.75
Metastases 46.6% 44.3% 24% 63.5% 16% 60.6% 50.5% 81% 51.3%
Outpatient/in-patient 15.6/84.4% 24.9/75.1% 6.2/93.8% 28.2/71.8% 9.2/90.8% 12.7 /87.3% 14.8/85.2% 9.6/90.4% 10.1/89.9%
WHO PS 0–1 49.8% 64.2% 47% 51.3% 40.7% 46.4% 45% 26.4% 48.4%
WHO PS 2–4 50.2% 35.8% 53% 48.7% 59.3% 53.6% 55% 73.6% 51.6%
6 Months WL
No 39.6% 53.7% 25.8% 31.6% 43.7% 39.3% 21% 34.6% 40.3%
0% 4 WL o5% 19.5% 22.1% 17.6% 20.9% 13.4% 15.6% 15.8% 16% 23%
5% X WL o10% 17.4% 11.9% 19.5% 24.5% 17.9% 17.2% 19% 19.8% 18%
10% X WL o15% 12.6% 6.9% 17.6% 14.4% 17% 13.1% 22.1% 11.1% 11.2%
415% 10.9% 5.4% 19.5% 8.6% 8% 14.8% 22.1% 18.5% 7.5%
Current BMI 24.1±4.7 24.7±4.7 22.7±4.5 24.1±4.1 24.9±4.8 24.5±5 22.8±4.3 24.9±4.8 24.2±4.8
o18.5 + p70 years 8.4% 5.2% 15.1% 6% 5.6% 8% 12% 15.3% 15.1%
o21 + 470 years 4% 3.6% 2.3% 7.4% 2.1% 1.6% 5% 4.7% 2.3%
%BMI X 30 11.1% 14.2% 8.1% 11.4% 14.8% 11.2% 6% 4.7% 8.1%
BMI 6 months previously 25.2±4.9 25.1±4.6 24.6±5.1 25.6±4.7 26±5.3 25.7±5.7 25±4.9 24.7±4.5 24.7±4.5
%BMI X 30 (every 6 months) 15% 13.2% 15.1% 18.3% 17.6% 17.3% 17.5% 13.1% 12.9%
Malnutrition 1364
None 69.1% 81.7% 54.4% 68.8% 65.8% 68% 50.5% 59.8% 73%
Present 30.9% 18.3% 45.6% 31.2% 34.2% 32% 49.5% 40.2% 27%
Moderate 18.6% 11.2% 22.5% 22% 26.3% 16.4% 26.3% 21.9% 18%
Severe 12.2% 7.1% 23.1% 9.2% 7.9% 15.6% 23.2% 18.3% 9%
Abbreviations: BMI¼body mass index; PS¼performance status; WHO¼World Health Organisation; WL¼weight loss.
aLeukaemia, lymphoma, myeloma.
bOvarian and
uterine cancers.
cCancers of the oesophagus, stomach and pancreas; liver carcinomas.
dProstate, urinary, brain, thyroid, testicular and kidney cancers; trunk and limb sarcomas;
melanoma; other thoracic or abdominal tumours; unclassified tumour.
Table 2B Treatments
Number of patients Percentage
Active treatment 1246
a 80.65
a
Surgery 437 (including 74 combination treatments) 28.3
a
Chemotherapy 680 (including 173 combination treatments) 44
a
Radiotherapy 167 (including 112 combination treatments) 10.8
a
Complication of
active treatment
70 4.53
Unknown 77 4.98
Others 299 19.35
Follow-up
examination
116 7.51
Palliative care 147 9.51
End-of-life care 15 0.97
Unknown 21 1.36
Total 1545 100.00
aA number of patients received combination regimens with two or more treatments
(chemotherapy, radiotherapy and/or surgery). Consequently, the sum of the different
treatment groups is superior to the overall number of patients actually receiving
active treatment.
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sDISCUSSION
In this prospective observational study, the prevalence of
malnutrition, defined as a function of two anthropometric
indicators, BMI and WL was 30.9%. This result applied to
patients from comprehensive cancer centres that are considered
as expert centres and may thus treat patients with more advanced
cancers. The most recent data in Europe are those of the German
hospital malnutrition study of 475 cancer patients (of 1886
hospitalised patients) published in 2006 (Pirlich et al, 2006).
Using subjective global assessment, the German investigators have
rated patients as malnourished (SGA B) or severely malnourished
(SGA C), with malnutrition rates of 37.6%. The median age was
63±14 years and 56% of patients were men, which is higher than
that in this study. A Dutch study published in 2001 included 1186
cancer patients (in 7606 patients, of whom 81% were hospitalised)
(Kruizenga et al, 2003). The prevalence of malnutrition, defined as
a 410% WL in the previous 6 months, was 21%. A French study
conducted in 2006 in 477 cancer patients has reported WLs410%
in 6 months (or 45% in 1 month) in 22.4% of patients (Nourissat
et al, 2007), whereas rates of 39.7% have been reported by Bozzetti
(2009) in an Italian population of 1000 patients with selected
cancers (digestive, lung or head-and-neck cancers). The higher
risk of malnutrition associated with tumours of the upper digestive
tract or head-and-neck cancers described in this study is in
agreement with that of most previous studies (Nitenberg and
Raynard, 2000; Kruizenga et al, 2003; Nourissat et al, 2007,
Bozzetti, 2009). Prevalence is generally lower in patients with
breast cancer. This population represented 24% of our study
sample; 18.3% were found malnourished, or even severely
malnourished, as 12.3% had X10% WL, which is more than twice
the rate reported by Dewys et al (1980) for patients investigated at
the beginning of chemotherapy. However, this high prevalence
could be due to the fact that 44% of our breast cancer patients had
metastatic disease. In this study, as in most papers describing the
epidemiology of malnutrition in large cancer patient populations, a
limitation could arise from the validity of the parameters used to
define malnutrition but, indeed, WL and low BMI are commonly
used and associated with outcome.
Table 3 Relationships between malnutrition and clinical data
Risk factors
%
Malnutrition
Odds
ratio
95%
CI P-value
Gender
Female 28 1
Male 35.3 1.4 1.1–1.8 0.004
Type of hospitalisation
Outpatient 20.8 1
In-patient 32.7 1.8 1.3–2.7 0.001
Age (years)
p70 29.7
470 35 0.08
Type of cancer
Breast 18.3 1
Head and neck 45.6 3.7 2.4–5.8 o0.0001
Colon-rectum 31.2 2 1.3–3.2 0.0019
Haematological 34.2 2.3 1.4–3.8 0.0004
Digestive 49.5 4.4 2.6–7.3 o0.0001
Gynaecological 32 2.1 1.3–3.4 0.0018
Lung 40.2 3 1.8–5.1 o0.0001
Type of stay
Curative treatment 26.8 1
Under evaluation 36.6 1.6 1.0–2.4 0.035
Palliative care 59.2 4 2.7–5.8 o0.0001
Metastases
No 27.8 1
Yes 34.3 1.4 1.1–1.7 0.0093
Radiotherapy
No 29.3 1
Yes 40.1 1.6 1.2–2.2 0.0024
Chemotherapy
No 28.9
Yes 32.4 0.16
Surgery
No 31.6
Yes 26 0.13
Obesity 6 months previously
BMI o30 28.5 1
BMI X30 38.8 1.6 1.2–2.2 0.0032
WHO PS
0 15.4 1
1 24.3 1.8 1.2–2.6 0.0037
2 38 3.4 2.3–4.9 o0.0001
3 50.2 5.5 3.6–8.4 o0.0001
4 46.7 4.8 2.7–8.4 o0.0001
0–1 19.6 1
2–3–4 43.3 3.1 2.4–4.0 o0.0001
Malnutrition % Antibiotic therapy
a
No 22.8 1
Yes 35.5 1.9 1.4–2.5 o0.0001
Abbreviations: BMI¼body mass index; CI¼confidence interval; PS¼performance
status; WHO¼World Health Organisation.
aWith the exception of antibiotic
prophylaxis for surgery.
Table 4 Factors independently associated with malnutrition
Risk factors Odds ratio 95% CI P-value
BMI X30 1.58 1.08–2.31 0.018
PS X2 2.71 2.30–6.70 o0.01
Digestive cancer
a 3.39 1.89–6.10 o0.01
Head and neck cancer 2.28 1.53–3.41 o0.01
Abbreviations: BMI¼body mass index; CI¼confidence interval; PS¼performance
status.
aOesophagus, stomach and pancreas cancers, liver carcinoma.
Table 5 Factors independently associated with mortality
Risk factors Odds ratio 95% CI P-value
Presence of metastases 2.21 1.3–3.73 0.03
Palliation
a 3.96 2.17–7.25 o0.001
Evaluation 2.80 1.38–5.69 0.004
Haematological malignancy 2.43 1.17–5.03 0.017
Gynaecological cancer 2.34 1.14–4.83 0.021
Lung cancer 2.85 1.37–5.93 0.005
WHO
PS 2 2.19 1.18–4.05 0.013
PS 3 4.12 2.2–7.72 o0.001
PS 4 8.77 4.08–18.9 o0.001
Severe malnutrition 2.47 1.40–4.36 0.002
Age 470 years 2.01 1.21–3.34 0.007
Abbreviations: CI¼confidence interval; PS¼performance status; WHO¼World
Health Organisation.
aAll terminally ill patients were dead at 2-months of follow-up.
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sLow BMI was reported in 12.4% of our patients; however,
only 7.3% of malnourished patients were diagnosed with this
parameter and, despite a significant WL (o10%), many patients
could not be classified as malnourished. Low BMI is thus not
significantly correlated with malnutrition. This is in agree-
ment with several other authors who have reported that only
10% of malnourished patients are detected when using the
BMI criterion, vs 30–40% when using the WL criterion (Kruizenga
et al, 2003; Nourissat et al, 2007). However, Kruizenga et al
(2003) have suggested that a low BMI is often associated
with malnutrition (OR¼6.01; 95% CI (4.92–7.33)), even if the
correlation between WL and BMI is poor and the discriminative
power of the test is low. This criterion thus remains relevant
for several reasons: calculating BMI can be used to (1) detect
malnourished patients in the absence of WL (one in four of
the 30.8% malnourished patients identified in this study);
(2) select specific populations at risk of increased mortality, such
as elderly patients with low BMI (Landi et al, 2000); and (3)
identify obese patients shown to be potentially at higher risk
of malnutrition.
Malnutrition in this study has several negative conse-
quences. First, it is associated with functional impairment, in
agreement with the literature (Dewys et al, 1980; Bozzetti, 2009).
It is also linked to other indicators associated with increased
cost burden on the health-care system. In univariate analysis,
the need for antibiotics was 1.87 higher in malnourished patients
(Po0.001), but this criterion did not remain significant in
multivariate analysis. Schneider et al (2004), who have examined
the correlation between nutritional status (evaluated using the
nutritional risk index NRI) and nosocomial infections, have
shown that the risk of infection is increased in patients with
moderate malnutrition (OR 1.46; 95% CI (1.2–2.1)), and especially
in those suffering from severe malnutrition (OR 4.98; 95% CI
(8.8–12.6)).
Malnutrition is also frequently associated with longer hospital
stays, which are indicative of higher costs (Norman et al, 2008). In
this study, the length of stay was found to be increased by 45% in
malnourished patients. This result is close to the 42% reported by
Pirlich et al (2006) in the German study, which included 25% of
patients with cancer, whereas other authors have reported even
higher increases (60%) in populations including 28% of cancer
patients (Correia and Waitzberg, 2003). Contrary to PS, length of
stay did not remain significantly correlated with malnutrition after
adjustment for potentially confounding factors. However, it is
generally admitted that nutritional support can reduce the LOS
and is consequently cost-effective for malnourished patients
(Tucker and Miguel, 1996; Johansen et al, 2004; Kruizenga et al,
2005).
The correlation between mortality and malnutrition is con-
sidered to be very high in cancer patients (Norman et al, 2008).
Dewys et al (1980) have evidenced an impact of malnutrition
on outcome in patients with only moderately impaired PS or
with limited tumour burden. Results of this study confirmed
the prognostic impact of the common factors independently
associated with mortality: PS, age 470 years, metastatic disease,
some tumour sites (blood, gynaecologic organs, lung, etc.) or the
reason for hospital admission (palliative care or evaluation).
Severe (but not moderate) malnutrition was found to be
significantly correlated with mortality (OR 2.47; 95% CI (1.4–
4.36); P¼0.002). Finally, patients for whom no weight and height
information was available were found to have higher mortality in
univariate analysis, but in these patients, PS is also higher (results
not shown). Similar information was obtained by Izawa et al
(2007) in frail elderly patients.
Indeed, in the present population, the major observation
was that obesity (BMI X30) 6 months before the study was
associated with an increased risk of malnutrition (OR 1.55; 95% CI
(1.06–2.27); P¼0.024). Obesity is a well-known risk factor in
many of the most prevalent tumours (Calle et al, 2003). Obesity has
also been considered as a factor of poor prognosis in many
studies (Dignam et al, 2006; Cleveland et al, 2007; Majed et al,
2008; Li et al, 2009). Particularly in patients with breast cancer,
obesity may be a reason for under-treatment because treat-
ment doses are not always adjusted to actual weight (Griggs et al,
2005). However, insufficient treatment is certainly not the only
factor linking bad prognosis to overweight and obesity during
cancer treatment, and the relationship between obesity, adipose
tissue function, inflammation, insulin resistance and tumour
growth is a major field of research (McTiernan, 2005; van
Kruijsdijk et al, 2009). Although it is recognised that weight
stabilisation during chemotherapy is associated with improvement
in survival (Andreyev et al, 1998; Ross et al, 2004), it is unlikely
that patients included in our study population were asked to lose
weight and that they have voluntarily done so. The recent
guidelines recommend to prevent therapy-associated WL during
therapy (Arends et al, 2006). More probably, patients with high
BMI were those more frequently exposed to significant WL
and malnutrition because patients and caregivers paid less
attention to this loss in case of obesity. Recently, Prado et al
(2008) have suggested that 15% of obese patients have sarcopaenia,
a complication associated with poorer functional status and inde-
pendently predictive of mortality (HR 4.2; 95% CI (2.4–4.7)). In
this study, the fact that malnutrition (mainly estimated from
WL) was associated with a poor functional status is probably
related to the occurrence of sarcopaenia. Hence, obesity, which
is a growing concern in the Western world and a major risk
factor for life-threatening diseases, is also perhaps associated
with a higher risk of malnutrition in cancer patients. With the
growing population of overweight and obese patients, it will
become a major challenge in the next decade to better diagnose
malnutrition, to develop new techniques to adapt treatment to
adequate body composition parameters (Prado et al, 2007) and
eventually to promote voluntary WL in severely obese patients,
without loss of lean body mass and impairment of the functional
status.
CONCLUSIONS
The data reported in this study confirm the high prevalence of
malnutrition in cancer patients (one out of three patients). This
morbidity related to disease or to treatment is associated with an
impaired functional status, more frequent use of antibiotics and
higher mortality. The economic consequences for hospitals are
substantial; the LOS is 45% longer for malnourished patients than
for others, most likely owing to poorer PS (high PS score). This
is also the first report of obesity as a possible risk factor for
malnutrition in a large non-selected population of cancer patients.
This information should be confirmed in future studies and the
mechanisms involved should be further explored, especially
because caregivers often fear that obesity may be associated with
underlying nutritional deficiency.
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